Gastro Florida

Summary

Gastro Florida is a medical facility located in Clearwater, Florida. This center is recognized for care of Ulcerative Colitis, Crohn's Disease, Colitis, Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease and other specialties. Gastro Florida is involved with conducting 45 clinical trials across 33 conditions. There are 3 research doctors associated with this hospital, such as Michael Weiss, Tejinder Glamour, MD, and Umesh Choudhry.

Top PIs

Clinical Trials running at Gastro Florida

Ulcerative Colitis

Crohn's Disease

Clostridium Difficile Infection

Nonalcoholic Steatohepatitis

Non-alcoholic Fatty Liver Disease

Crohn's disease

Diarrhea

Clostridium difficile infection

C. diff infection

Colitis

Vedolizumab

for Ulcerative Colitis and Crohn's Disease

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 months (14 weeks) of treatment with Vedolizumab (this is called remission). Participants will be treated with Vedolizumab for approximately 1 year (50 weeks). During the first 1.5 months (6 weeks), participants will receive Vedolizumab as an infusion in the vein (called intravenously). After this, participants will receive Vedolizumab as an injection under the skin (called subcutaneously) for the rest of the treatment. Participants for whom the treatment does not seem to work well after 3.5 months (14 weeks) will stop treatment with Vedolizumab and can change to another treatment and also there will be additional required visits at 6 months (26 weeks) and at 1 year (52 weeks). All participants will be checked again 4.5 months (18 weeks) after their last treatment with Vedolizumab. During the study, participants will visit their study clinic several times.

Recruiting

3 awards

Phase 4

2 criteria

RO7790121

for Ulcerative Colitis

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

Recruiting

1 award

Phase 3

3 criteria

Etrasimod

for Ulcerative Colitis

The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod. All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer. The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.

Recruiting

1 award

N/A

3 criteria